Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 20/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 3/20 | 0.67 |
| ▸ | DRD2 | P14416 | 14/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529805 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4521381 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| Hydrochloric Acid SCHEMBL4526059 | 0.98 | ADRB2 (0.98) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4518404 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| Hydrochloric Acid SCHEMBL4514960 | 0.88 | ADRB2 (0.98) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4526560 | 0.88 | ADRB2 (1.00) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4509402 | 0.87 | ADRB2 (0.78) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4519481 | 0.87 | ADRB2 (0.78) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4509397 | 0.87 | ADRB2 (0.78) | ADRB2ADRB1DRD2ADRA1DDRD3 | |
| SCHEMBL4519478 | 0.87 | ADRB2 (0.78) | ADRB2ADRB1DRD2ADRA1DDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221653-A1 | 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRA1D 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.